Given the relatively high 10-year survival of EC in England of 71.6%, the identification of LS provides valuable opportunities for the prevention of further primary cancers.7 28 29 For example, delays in commencing aspirin prophylaxis and colonoscopy screening for female LS carriers in this age range could lead to CRCs being diagnosed at later stages, with the incidence of CRC between 60 and 70 years of age being 11.9% and 15.7% for MLH1 and MSH2 female PV carriers, respectively.1 This evidence concerns the gene MSH2 and cancer.